Business Development

Strategic Partnering Opportunities:

Actavalon is applying its proprietary computational, biological, and chemistry methods to develop novel small molecules with enhanced potency, bioavailability and solubility for reactivation of mutationally inactivated p53 tumor suppressor proteins. Actavalon’s focus is to develop a robust drug pipeline for clinical evaluation.

Actavalon’s business strategy is to establish collaborative pharmaceutical partnerships to drive our new chemical entities through development and commercialization to address critical medical needs.